BS_5PEFNDCY
Glial-neuronal tumor NOS
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Glial-neuronal tumor NOS
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Glial-neuronal tumor NOS
- age_years
- 7.822
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.426
- PANCREAS_BETA_CELLS+0.369
- MYOGENESIS+0.335
- APICAL_SURFACE+0.314
- COAGULATION+0.275
- INTERFERON_ALPHA_RESPONSE+0.269
- KRAS_SIGNALING_UP+0.209
- INFLAMMATORY_RESPONSE+0.203
- BILE_ACID_METABOLISM+0.198
- XENOBIOTIC_METABOLISM+0.160
Top 10 suppressed
- MYC_TARGETS_V1-0.661
- MYC_TARGETS_V2-0.653
- E2F_TARGETS-0.605
- OXIDATIVE_PHOSPHORYLATION-0.578
- G2M_CHECKPOINT-0.560
- DNA_REPAIR-0.555
- UNFOLDED_PROTEIN_RESPONSE-0.528
- WNT_BETA_CATENIN_SIGNALING-0.382
- MTORC1_SIGNALING-0.371
- MITOTIC_SPINDLE-0.369
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1ZVXF5FE | pilocytic astrocytoma | — | 0.941 |
| 2 | BS_Y7F9E2E9 | low-grade glioma | — | 0.926 |
| 3 | BS_398KYV92 | Meningioma | — | 0.922 |
| 4 | MDT-AP-0208 | Med | Medulloblastoma | 0.921 |
| 5 | s_150324_2b | EPN | Posterior Fossa EPN | 0.914 |
| 6 | MNG613 | — | — | 0.913 |
| 7 | SRR1417202 | GTEX | — | 0.906 |
| 8 | SRR1440962 | GTEX | — | 0.905 |
| 9 | BS_912NX4Y0 | Ganglioglioma | — | 0.904 |
| 10 | SRR1338627 | GTEX | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.426 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.369 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.335 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.314 | Temsirolimus | — uncovered |
| COAGULATION | 0.275 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.269 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.209 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.203 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.198 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.148 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.131 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.123 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.095 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.083 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.082 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.072 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.059 | Remibrutinib | — uncovered |